JP2019180409A - Composition for locomotive syndrome improvement - Google Patents

Abstract

To provide a composition having superior functionality by using natural plant raw materials which can adapt to utilization form such as food.SOLUTION: Lindera umbellata extract is used as an active component of a composition for locomotive syndrome improvement. It is preferable that the Lindera umbellata extract has a function suppressing depression of bone density, a function suppressing depression of muscle amount, or a function suppressing depression of a proteoglycan amount at a joint. It is preferable that the Lindera umbellata extract contains hot water extract of the Lindera umbellata.SELECTED DRAWING: None

Description

  The present invention relates to a composition for improving locomotive syndrome, which contains a natural plant material as an active ingredient.

  The camphor tree is a deciduous shrub that is widely distributed from the southern part of Hokkaido to Kyushu. Its branches and leaves are called coral and have long been used as a raw material for herbal medicines and folk medicines that help the digestive system. Has been. In addition, it has a good fragrance, and high-grade toothpicks to be added to Japanese sweets and essential oils collected by steam distillation are used for aroma.

  In the past, various functionalities have been reported for this black moji. For example, Patent Document 1 describes a melanin production inhibitor composed of an extract of the camphor tree barkwood bark. Patent Document 2 describes an anti-Helicobacter pylori agent containing a plant extract such as black moji as an active ingredient. Patent Document 3 describes an alcohol disorder preventive agent containing a pulverized product of one part of a camphor family such as black moji or a fat-soluble solvent extract thereof. Patent Document 4 describes a protease inhibitor containing, as an active ingredient, an extract of a plant belonging to the genus Lindera Thunb. Patent Document 5 describes a cosmetic composition characterized by containing steam distilled water of a camphor family such as black moji. Patent Document 6 describes an anti-influenza virus agent containing a plant extract such as black moji as an active ingredient. Patent Document 7 describes an antihypertensive agent characterized by containing a plant such as black moji or an extract thereof. Patent Document 8 describes a Maillard reaction inhibitor containing a plant extract such as black moji as an active ingredient. Patent Document 9 describes an IgE production-suppressing composition and an antiallergic composition characterized by containing a processed product of a plant such as black moji. Patent Document 10 describes a ceramidase activity inhibitor characterized by containing a plant extract such as black moji as an active ingredient.

JP 07-277951 A JP-A-11-001429 JP 2000-344675 A JP 2001-122728 A JP 2001-226218 A JP 2004-059463 A JP 2007-051129 A JP 2010-077123 A JP 2010-180141 A JP 2017-124984 A

  An object of the present invention is to provide a composition having excellent functionality using a natural plant material that can be adapted to the form of utilization of food or the like.

  As a result of intensive studies to achieve the above-mentioned object, the present inventors have found that the chromophore extract extracted from the camphor of the camphoraceae plant has an action of suppressing a decrease in bone density, an effect of suppressing a decrease in muscle mass, The present inventors have found an action to suppress a decrease in the amount of proteoglycan and have completed the present invention.

  That is, the present invention firstly provides a composition for improving locomotive syndrome, characterized by containing chromomydi extract as an active ingredient.

  In the above composition for improving locomotive syndrome, the composition is preferably used for bone maintenance or strengthening.

  In the locomotive syndrome improving composition, the composition is preferably used for muscle maintenance.

  In the composition for improving locomotive syndrome, the composition is preferably used for joint protection.

  Moreover, in the said composition for improving locomotive syndrome, it is preferable that the said chromomy extract contains the hot water extract of chromomy.

  According to the present invention, a black moji extract extracted from a camphor tree of the camphor family has an effect of suppressing a decrease in bone density, an effect of suppressing a decrease in muscle mass, and an effect of suppressing a decrease in the amount of proteoglycan in a joint. It became clear. Thereby, the composition which has the outstanding functionality, such as a composition for locomotive syndrome improvement, can be provided by using the chromophore extract as an active ingredient. The composition is also suitable for use forms such as food.

It is a graph which shows the result of having verified the influence which the administration of the chromomy extract to a lifestyle-related disease model mouse gives to a bone density in the test example 1, (a) is a graph which shows the result regarding the chromomy extract administration group, (b) FIG. 4 is a chart showing the results of positive controls with reference drugs. It is a graph which shows the result of having verified the influence which the administration of the black moji extract to the lifestyle-related disease model mouse has on muscle mass in Test Example 2. It is a graph which shows an example of the result of having verified the amount of proteoglycan expressed in the joint part of the normal rat in Experiment 3, (a) is a visible image of microscopic observation of a safranin O-stained specimen, (b) is visible The image is a digitally processed image in which a red stained portion is whitened, and (c) is an image in which a visible image is digitally processed and a portion of the red stained portion in which red is dyed darker is made red. It is a graph which shows an example of the result of having verified the amount of proteoglycan expressed in the joint part of the diabetes disease state model rat in Test example 3, (a) is a visible image of microscopic observation of a safranin O-stained specimen, (b) (C) is an image obtained by digitally processing a visible image and whitening a red-stained portion, and (c) is an image obtained by digitally processing the visible image and changing a red-stained portion of a red-stained portion to a red color. is there. It is a graph which shows an example of the result of having verified the influence which the administration of the chromodi extract to the diabetic state model rat gives to the amount of proteoglycan of a joint site in Test Example 3, (a) is a visible image of microscopic observation of a safranin O stained specimen (B) is an image obtained by digitally processing a visible image and whitening a red-stained portion, and (c) is a digitally-processed image of the visible image and red in the red-stained portion is dyed darker. This is a red image of the part. It is a chart which shows an example of the result of having verified the amount of proteoglycan expressed in the joint part of the normal mouse in Test Example 4, (a) is a visible image of microscopic observation of a safranin O-stained specimen, (b) is visible The image is a digitally processed image in which a red stained portion is whitened, and (c) is an image in which a visible image is digitally processed and a portion of the red stained portion in which red is dyed darker is made red. It is a graph which shows an example of the result of having verified the amount of proteoglycan expressed in the joint site | part of the lifestyle-related disease model mouse in Experiment 4, (a) is a visible image of the microscopic observation of a safranin O dyeing specimen, (b) Is an image obtained by digitally processing a visible image and whitening a red-stained portion, and (c) is an image obtained by digitally processing the visible image and changing a red-stained portion of a red-stained portion to be red. It is. It is a graph which shows an example of the result of having verified the influence which the administration of the chromophore extract to the lifestyle-related disease model mouse in the test example 4 has on the proteoglycan amount of a joint part, (a) is visible of the microscopic observation of the safranin O dyeing specimen. (B) is an image obtained by digitally processing a visible image and whitening a red-stained portion, and (c) is a digitally-processed image of the visible image, and red in the red-stained portion is dyed darker. It is an image that the red part is red. It is a graph which shows an example of the result of having verified the influence which the administration of metformin hydrochloride which is a hypoglycemic agent to a lifestyle-related disease model mouse has on the proteoglycan amount of a joint site in Test Example 4, (a) is a safranin O-stained specimen (B) is an image in which the visible image is digitally processed and the red stained portion is whitened. (C) is a digital image of the visible image that is processed in red. It is an image in which the part where red is dyed darker is red. It is a table | surface which shows the result compared with the relative value when the average value of a normal group is set to 100 about the staining area by the safranin O dyeing | staining in the knee joint part in Experiment 4. FIG.

  The present invention finds that the chromophore extract extracted from the camphor of the camphoraceae plant has an action of suppressing a decrease in bone density, an effect of suppressing a decrease in muscle mass, and an effect of suppressing a decrease in the amount of proteoglycan in the joint, Based on this, a composition for improving locomotive syndrome and the like are provided. The composition for improving locomotive syndrome is used for bone maintenance or strengthening, muscle maintenance, or joint protection. That is, the present invention provides a composition having functionality that acts on a living body of a human being or an animal, and hereinafter, it may be referred to as “functional composition” or simply “composition” for convenience of explanation.

  The base of the black moji extract used in the present invention may be a plant belonging to the genus Lindera, for example, black moji (Lindera umbellata Thunb.), Psyllium umbellata var. Membranacea (Maxim.) Momi. , S. cerevisiae (Lindera umbellata var. Kurodaji (Lindera benz) oin (L.) Blume), Yamadae Bee (Lindera glauca Blume), Dankobai (Lindra obtusiloba Blume), Tendai Yaku (Lindera strechnifolia (Sieb. et Zucc.) F. and others. Among these, Kuromoji (Lindera umbellata Thunb.) Is particularly preferable.

  The part of the plant is not particularly limited, and examples thereof include trunks, trunks, branches and leaves, leaves, bark, roots, rhizomes, root barks, stems, flowers, seeds, pericarp, flesh, fruits, above-ground parts, underground parts, all Examples include trees. Among these, a trunk branch is particularly preferable.

  In the present invention, an extract is prepared based on the above plant and used as an active ingredient. More specifically, chromomy extract, which is an extract of chromomy, is used as the above-mentioned functional component. As an extraction solvent used for the extraction, an appropriate solvent may be used as appropriate, and typically water, an organic solvent, or a water-containing organic solvent is used. In particular, water is more preferable. Examples of the organic solvent include, for example, lower aliphatic alcohols such as methanol and ethanol, and organic solvents compatible with water such as ethyl acetate, acetone, chloroform, and n-hexane. These organic solvents can be used in combination of two or more. When a water-containing organic solvent is used, the content of the organic solvent may be in the range of more than 0% to less than 100% by volume, but is preferably 50% by volume or less, preferably 5 to 50% by volume. Is more preferable, 10 to 45 volume% is still more preferable, and 20 to 40 volume% is especially preferable. When ethanol or hydrous ethanol is used for the extraction, hydrous ethanol having an ethanol content of 50% by volume or less is preferred, hydrous ethanol having an ethanol content of 5 to 50% by volume is more preferred, and hydrous ethanol having an ethanol content of 10 to 45% by volume. Ethanol is even more preferable, and hydrous ethanol having an ethanol content of 20 to 40% by volume is particularly preferable.

  As a specific method of extraction, a general extraction means can be employed, for example, after appropriately cutting a dried product of the trunk branch of black moji, 1 to 50 times, preferably 5 to 5 times its total mass. A 20-fold amount of extraction solvent is added, and immersion and heating extraction can be performed in the range of room temperature to the boiling point of the solvent used for about 1 to 24 hours. If necessary, extraction may be performed under pressure. After extraction, filtration may be performed as necessary, the obtained extract may be concentrated under reduced pressure, or lyophilized to remove the solvent, and the target extract is appropriately prepared. be able to. The drying means may be reduced pressure drying or spray drying. For example, when the extraction solvent is water, the extraction temperature is preferably 5 to 100 ° C, more preferably 30 to 100 ° C, and still more preferably 50 to 100 ° C. When the extraction solvent is ethanol or hydrous ethanol, the extraction temperature is preferably 5 to 70 ° C, more preferably 30 to 70 ° C, and still more preferably 50 to 70 ° C. .

  The chromophore extract obtained as described above has an effect of suppressing a decrease in bone density, an effect of suppressing a decrease in muscle mass, and an effect of suppressing a decrease in the amount of proteoglycan in a joint, as shown in Examples described later. Are better. Therefore, it can be effectively used to improve the locomotive syndrome by acting on the living body. The functional composition according to the present invention can also be used effectively for bone maintenance or strengthening, muscle maintenance or joint protection. “Improvement” means that the application of the composition according to the present invention makes various symptoms and physical conditions better for the application as compared to the case where the composition according to the present invention is not applied. It also includes preventive application to maintain a better state without breaking it.

  Here, in general, locomotive syndrome refers to a state in which the mobility function is reduced because one or more functions of the exercise devices such as bones, muscles, and joints are reduced. Since these muscles, bones, and joints support each other, even if an attempt is made to improve some of the functions, it is difficult to lead to a significant improvement in movement function. For example, if the skeletal muscles drop due to lack of exercise, the muscles do not stimulate the bones and the bones weaken, so even if you try to improve only the bones, if the muscles are weakening, the bones will not improve and the movement function will be greatly improved Cannot be expected. When the functions of a plurality of parts are reduced in this way, it can be said that it is more effective to improve the plurality of parts together than to improve any one of them. According to the present invention, the effect of improving the function can be expected for any of a plurality of parts such as bones, muscles, and joints, and thus the state in which the movement function is reduced can be effectively improved.

  The composition according to the present invention may be administered orally, for example. The form for oral administration is not particularly limited, and the solid form, liquid form, emulsion form using the above-described chromomy extract and a base material, carrier, solvent, etc. that are acceptable for oral intake. It can be in the form of a paste, jelly, or the like. Moreover, it can be set as forms, such as a tablet, a granule, a powder, a liquid agent, a capsule. Alternatively, the above-described chromodi extract can be mixed with an appropriate carrier, preferably a fatty acid triglyceride, and filled in a soft capsule or the like in a liquid state.

  On the other hand, the composition according to the present invention may be administered parenterally, for example, for external use on the skin. The form for that is not particularly limited, and forms of solution, emulsion, forms added with dispersing agents, suspensions, stabilizers, forms of poultices, lotions, ointments, tinctures, creams, etc. Can be used.

  Formulation is not limited to oral and parenteral preparations, and if necessary, commonly used excipients, binders, disintegrants, lubricants, stabilizers, surfactants, dissolution agents Auxiliary agent, reducing agent, buffering agent, adsorbent, fluidizer, antistatic agent, antioxidant, sweetener, corrigent, cooling agent, sunscreen agent, flavoring agent, fragrance, fragrance, coating agent, plastic One or more preparation additives such as an agent may be appropriately selected and added.

  Specific examples of such formulation additives include crystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, croscarmellose sodium, maltodextrin, ethylcellulose, lactose, sorbitol, silicic anhydride, and silicic acid. Magnesium, hydroxypropyl cellulose, stearic acid, oleic acid, liquid paraffin, dicalcium phosphate, dibutyl sebacate, macrogol, propylene glycol, corn starch, starch, pregelatinized starch, gelatin, popidone, crospovidone, glycerin, polysorbate 80, citrus Acid, acesulfame potassium, aspartame, sodium carbonate, talc, magnesium stearate, calcium stearate, etc. That.

  In the composition for improving locomotive syndrome according to the present invention, the above-described chromophore extract may be used as an active ingredient, and other ingredients such as vitamins, minerals, amino acids, fatty acids, and dietary fibers may be added.

  In the composition for improving locomotive syndrome according to the present invention, it is preferable to contain 0.001 to 99% by mass, preferably 0.01 to 70% by mass, of the above-mentioned chromody extract as an active ingredient in terms of dry matter. It is more preferable, and it is still more preferable to contain 0.05-50 mass%.

  When the composition for improving locomotive syndrome according to the present invention is orally administered to humans, the dosage varies depending on the age and body weight, but for example, it is 1. It is preferably about 0 mg to 50 g, more preferably about 5.0 mg to 20 g, and even more preferably about 10 mg to 10 g.

  There is no restriction | limiting in particular as a usage form of the composition for locomotive syndrome improvement by this invention. For example, it may be in the form of functional foods, supplements, pharmaceuticals, cosmetics and the like. These forms are not limited to human use, and may be animal use. More specifically, functional indication foods, foods for specified health use, health foods, functional foods, dietary supplements, supplements, pharmaceuticals, quasi-drugs, cosmetics, health foods for animals, functional foods for animals, animals It can be used in various product forms such as nutritional supplements for animals, animal supplements, veterinary drugs, quasi-drugs for animals, animal cosmetics, or in combination with these products.

  The use form of the composition for improving locomotive syndrome according to the present invention may be in the form of a food composition. That is, it can be made into a food composition for exhibiting a predetermined functionality by blending a predetermined amount of the above-described black moji extract into food and drink. Specifically, for example, as solid, powder, granule, various confectionery such as biscuits, cookies, cakes, snacks, rice crackers, bread, powdered beverages (powdered coffee, powdered cocoa, etc.), rice cakes , Caramel and the like, but are not limited thereto. Examples of liquid, emulsified, pasty, and jelly-like products include various products such as drinks, jelly, and mousse, and medicinal liquors, but are not limited thereto. Furthermore, the form of the composition for food addition used in order to mix | blend with these food and drink may be sufficient.

  EXAMPLES The present invention will be described more specifically with reference to the following examples. However, these examples do not limit the scope of the present invention.

[Preparation Example 1]
After cutting the dried material of the trunk branches of black moji (Lindera umbellata Thunb.), 10 times the amount of water was added to the total mass and heated, followed by immersion and extraction by heating for 1 hour after boiling. After extraction, insoluble matters were removed by filtration, and the resulting extract was concentrated under reduced pressure, and the extraction solvent was removed by lyophilization to obtain a dry powdered chromodi extract.

<Test Example 1>
Using the black moji extract powder (hot water extract) obtained in Preparation Example 1, the effect on bone density was verified.

  For the evaluation, C57BLKS / J Iar- + Lwprdb / + Lwprdb (db / db mouse), which is a lifestyle-related disease model mouse, was used. When compared with C57BLKS / J Iar-m + / + Lwprdb (db / + mice), which is a normal mouse, lifestyle-related disease model mice show a decrease in bone density. Please evaluate.

  Specifically, the animals used (lifestyle disease model mice and normal mice, male, 7 weeks old) were pre-bred for 1 week, then fresh air, temperature 24 ± 2 ° C, humidity: 50 ± 10%, lighting time : Reared in a breeding room in a barrier facility set at 12 hours (7-19 o'clock) per day. The feed was a radiation-sterilized solid feed (Lab MR Stock, Nippon Agricultural Industry Co., Ltd.), and the drinking water was freely ingested using chlorinated well water using a water bottle. The normal group and the control group were orally administered with distilled water, the chromodi extract extract group was orally administered with 300 mg / kg / day daily for 12 weeks using an oral sonde. As a reference drug, metformin hydrochloride, which is a hypoglycemic agent, was orally administered daily at a dose of 350 mg / kg / day for 12 weeks using an oral sonde. After completion of the administration period, whole blood was collected from the heart under isoflurane inhalation anesthesia, after which the tibia of the right hind limb was collected and stored frozen until bone density measurement. The bone density was measured using a microfocus X-ray CT scanner tomography (“Scan Xmate-L090”, Comscan Techno), voltage 75 kV, current 100 μA, magnification 9.667 times, resolution 10.334 μm / pixel. The cancellous bone at the proximal end of the tibia was photographed under the condition of a slice thickness of 10.334 μm, analyzed by analysis software (“TRI / 3D-BON”, Ratoc System Engineering Co., Ltd.), and the bone density was calculated by the following formula .

  Bone density (%) = cancellous bone volume / bone tissue volume × 100 (1)

  The results of three cases for each test group are shown in FIG. 1 as the average value and standard deviation of bone density. In addition, the test of the positive control by the chromophore extract administration group and the reference drug was conducted on separate days for the normal group and the control group.

  As a result, as shown in FIG. 1 (a), it is clear that the administration of the black moji extract suppresses the decrease in bone density of lifestyle-related disease model mice and maintains the bone density to the level of bone density of normal mice. It became. On the other hand, as shown in FIG. 1 (b), the administration of the hypoglycemic agent used as a reference drug did not suppress the decrease in bone density.

<Test Example 2>
Using the black moji extract powder (hot water extract) obtained in Preparation Example 1, the effect on muscle mass was verified.

  For the evaluation, C57BLKS / J Iar- + Lwprdb / + Lwprdb (db / db mouse), which is a lifestyle-related disease model mouse, was used. And when compared with C57BLKS / J Iar-m + / + Lwprdb (db / + mice), which is a normal mouse, lifestyle-related disease model mice show a decrease in muscle mass. Please evaluate.

  Specifically, the animals used, the preliminary breeding, the breeding environment, the feeding and water supply, and the administration method of the black moji extract were all the same as in Test Example 1. However, the administration group of two types of dosage of 100 mg / kg / day and 300 mg / kg / day was provided as a chromomy extract administration group. As a reference drug, metformin hydrochloride, which is a hypoglycemic agent, was orally administered daily at a dose of 350 mg / kg / day for 12 weeks using an oral sonde. After completion of the administration period, whole blood was collected from the heart under isoflurane inhalation anesthesia, and then the gastrocnemius muscle was collected and weighed.

  The results of 9 to 10 cases for each test group are shown in FIG. 2 as the mean value and standard deviation of gastrocnemius muscle weight.

  As a result, as shown in FIG. 2, the muscle mass of the lifestyle-related disease model mice was increased by the administration of the black moji extract, particularly in the administration group of the dose of 300 mg / kg / day. On the other hand, administration of a hypoglycemic agent used as a reference drug did not increase muscle mass.

<Test Example 3>
Using the black moji extract powder (hot water extract) obtained in Preparation Example 1, the effect on the proteoglycan amount at the joint site was verified.

  In the evaluation, streptozotocin (STZ: streptozotocin) was intraperitoneally injected at a dose of 60 mg / kg / day to the animals used (Slc: SD rat, male, 6 weeks old), and the blood glucose level was measured 3 days after the administration. An animal having a blood glucose level of 300 mg / dL or more was used as a diabetes disease state model. Then, when compared with normal rats not administered with streptozotocin, diabetic state model rats showed a decrease in the amount of proteoglycan in the joint region, and it was evaluated whether chromodi extract can suppress this.

  Specifically, the animals used (Slc: SD rat, male, 6 weeks old) were pre-bred for 1 week, then fresh air, temperature 24 ± 2 ° C., humidity: 50 ± 10%, illumination time: 12 per day It was raised in a breeding room in the barrier facility set at time (7-19 o'clock). The feed was a radiation-sterilized solid feed (Lab MR Stock, Nippon Agricultural Industry Co., Ltd.), and the drinking water was freely ingested using chlorinated well water using a water bottle. The normal group and the control group were orally administered with distilled water, and the chromodi extract extract group was orally administered with 300 mg / kg / day daily for 8 weeks using an oral sonde. After completion of the administration period, whole blood was collected from the abdominal aorta under isoflurane inhalation anesthesia, and then the tibia and femur of the left hind limb were stored in 10% neutral buffered formalin solution without separating the knee joint. After demineralizing the specimen with EDTA, a paraffin block was prepared, and a microtome (LEICA SM200R) was sliced to a thickness of 3 μm to prepare a safranin O-stained specimen.

  The proteoglycan stained red by safranin O staining was microscopically observed ("Digital Microscope VH-S30", KEYENCE). Also, the obtained image is analyzed by image analysis software (ImageJ), the part where red staining can be visually recognized in the knee joint part is extracted, and the area and the part of which staining is dyed darker (predetermined by ImageJ software) The color density range was selected).

  FIG. 3A shows an example of results in normal rats not administered with streptozotocin. Moreover, FIG. 3B shows an example of the result in a diabetic condition model rat administered with streptozotocin. Moreover, FIG. 3C shows an example of the results when chromodi extract is administered to diabetic pathological model rats.

  As can be seen from a comparison between FIG. 3A and FIG. 3B, the area of the portion where the proteoglycan expressed in the joint site is darkly stained in the diabetic state model rat compared to the normal rat. This indicates that the amount of proteoglycan in the joint site is decreased in diabetic state model rats compared to normal rats. On the other hand, as shown in FIG. 3C, when the chromodi extract was administered to the diabetic state model rat, the area of the portion where the proteoglycan was stained deeply recovered. Therefore, it became clear that the decrease in the amount of proteoglycan at the joint site in diabetic model rats can be suppressed by administration of chromodi extract.

<Test Example 4>
Using the black moji extract powder (hot water extract) obtained in Preparation Example 1, the effect on the proteoglycan amount at the joint site was verified.

  For the evaluation, the same lifestyle-related disease model mice as in Test Example 2 were used. When compared with normal mice, lifestyle-related disease model mice showed a decrease in the amount of proteoglycans at joint sites, and it was evaluated whether or not chromodi extract can suppress this.

  Specifically, the animals used, the preliminary breeding, the breeding environment, the feeding and water supply, and the administration method of the black moji extract were all the same as in Test Example 1. However, the administration group of 300 mg / kg / day is provided as the administration group of chromomy extract, and metformin hydrochloride as a hypoglycemic agent is used as a reference drug for 12 weeks using an oral sonde at a dosage of 350 mg / kg / day. Measurement was carried out in the same manner as in Test Example 3 except that it was orally administered every day and added as a positive control.

  FIG. 4A shows an example of results in normal mice. FIG. 4B shows an example of results in a lifestyle-related disease model mouse. Moreover, FIG. 4C shows an example of the results when a chromodis extract is administered in a lifestyle-related disease model mouse. FIG. 4D shows an example of the results when metformin hydrochloride, which is a hypoglycemic agent, is administered to lifestyle-related disease model mice. Further, in FIG. 5, safranin O staining at the knee joint portion was performed on 6 test animals in each group, and the area of the portion where staining was darker was obtained in the same manner as in Test Example 3, and the average of the normal group was obtained. The result of the comparison with relative values when the value is 100 is shown.

  The result was the same as the result of Test Example 3. That is, as seen in the comparison between FIG. 4A and FIG. 4B and FIG. 5, in the lifestyle-related disease model mouse, the area of the portion where the proteoglycan expressed in the joint site is deeply stained is reduced as compared with the normal mouse. This indicates that the amount of proteoglycan in the joint region is decreased in the lifestyle-related disease model mice as compared to the normal mice. On the other hand, as shown in FIGS. 4C and 5, when the chromophore extract was administered to lifestyle-related disease model mice, the area of the portion where the proteoglycan was stained deeply recovered. Therefore, it was clarified that the decrease in the amount of proteoglycan in the joint region can be suppressed by administration of chromodi extract in the lifestyle-related disease model mice as well as the results of the diabetic state model rats. On the other hand, as shown in FIG. 4D and FIG. 5, in the administration of the hypoglycemic agent used as the reference drug, the recovery of the area of proteoglycan staining by safranin O staining was limited.

(Prescription Example 1)
A cocoon extract containing chromomy extract was prepared with the composition shown below.
(1) 飴:
(Composition) (Parts by weight)
Powdered sorbitol 89.70
Fragrance 0.25
Chromoji extract powder of Preparation Example 10.00
Sorbitol seed 0.05
Total amount 100.00

(Prescription example 2)
A gum containing a chromodis extract having the composition shown below was prepared.
(2) Gum:
(Composition) (Parts by weight)
Gum base 20.00
Calcium carbonate 2.00
Stevioside 0.10
Chromoji extract powder of Preparation Example 10.00
Lactose 66.90
Fragrance 1.00
Total amount 100.00

(Prescription Example 3)
A caramel containing a black moji extract with the composition shown below was prepared.
(3) Caramel:
(Composition) (Parts by weight)
Granulated sugar 32.00
Minamata 20.00
Milk powder 30.00
Hardened oil 4.00
Salt 0.60
Perfume 0.03
Water 3.37
Chromoji extract powder of Preparation Example 10.00
Total amount 100.00

(Prescription Example 4)
A carbonated beverage containing chromomy extract with the composition shown below was prepared.
(4) Carbonated drink:
(Composition) (Parts by weight)
Granulated sugar 8.00
Concentrated lemon juice 1.00
L-ascorbic acid 0.10
Citric acid 0.09
Sodium citrate 0.05
Coloring agent 0.05
Carbonated water 80.71
Chromoji extract powder of Preparation Example 10.00
Total amount 100.00

(Prescription Example 5)
Juice containing chromomy extract with the composition shown below was prepared.
(5) Juice:
(Composition) (Parts by weight)
Frozen concentrated orange juice 5.00
Fructose glucose liquid sugar 1.00
Citric acid 0.10
L-ascorbic acid 0.09
Chromoji extract powder of Preparation Example 10.00
Fragrance 0.20
Dye 0.10
Water 83.51
Total amount 100.00

(Prescription Example 6)
A lactic acid bacteria beverage containing a black moji extract with the composition shown below was prepared.
(6) Lactic acid bacteria beverage:
(Composition) (Parts by weight)
Milk solid 21% fermented milk 14.76
Fructose dextrose liquid sugar 13.31
Pectin 0.50
Citric acid 0.08
Fragrance 0.15
Water 61.20
Chromoji extract powder of Preparation Example 10.00
Total amount 100.00

(Prescription Example 7)
An alcoholic beverage containing a black moji extract with the composition shown below was prepared.
(7) Alcoholic beverages:
(Composition) (Parts by weight)
50% ethanol 32.00
Sugar 8.60
Fruit juice 2.40
Chromoji extract powder of Preparation Example 10.00
Water 47.00
Total amount 100.00

Claims (5)

  A composition for improving locomotive syndrome, characterized by containing chromody extract as an active ingredient.   The composition for improving locomotive syndrome according to claim 1, which is used for bone maintenance or strengthening.   The composition for improving locomotive syndrome according to claim 1, which is used for muscle maintenance.   The composition for improving locomotive syndrome according to claim 1, which is used for joint protection.   The composition for improving locomotive syndrome according to any one of claims 1 to 4, wherein the chromomy extract contains a hot water extract of chromomy.